LLY ▼ -0.2% - Eli Lilly and Company
$LLY - Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
29-SEP-2026 06:00 PM ET
Share this post
More filings for $LLY
LLY ▼ -1.4% - Eli Lilly and CompanyOct 19, 2026LLY ▲ +0.4% - Eli Lilly and CompanyOct 18, 2026LLY ▲ +3.8% - Eli Lilly and CompanyOct 15, 2026LLY ▲ +1.3% - Eli Lilly and CompanyOct 15, 2026LLY ▲ +3.5% - Eli Lilly and CompanyOct 14, 2026LLY ▼ -0.5% - Eli Lilly and CompanyOct 9, 2026
View full $LLY filing history →💬 Comments
Loading comments…
Leave a comment